GlaxoSmithKline has reached a confidential Zantac cancer lawsuit settlement agreement resolving four cases that were scheduled to go to trial in California beginning next month.
A Zantac cancer lawsuit filed in California will go before a jury in November, however no specific case has yet been selected, according to a Reuters report.
A Zantac bladder cancer lawsuit scheduled to go to trial next month in California has been resolved through a confidential settlement agreement, GlaxoSmithKline says.
A California judge will allow Zantac lawsuits to move forward after allowing plaintiffs' expert witnesses to testify.
A House lawmaker is asking FDA whether it plans to investigate GlaxoSmithKline for potentially hiding cancer risks from Zantac for decades in order to maintain profits.
An investigative report indicates GlaxoSmithKline knew Zantac could transform into NDMA, a known cancer-causing chemical, since the drug was first developed, but never told the FDA.
Dozens of Zantac lawsuits filed in New York state courts have been consolidated for pretrial proceedings over claims the recalled heartburn drug may cause cancer.
Despite dismissal of federal Zantac lawsuits, plaintiffs continue to file claims in state courts.
Parties have reportedly reached a settlement agreement to resolve the first Zantac lawsuit scheduled to go to trial in California state court.
A judge has ordered all federal Zantac lawsuits dismissed after questioning the science behind claims that the recalled heartburn drug is linked to an increased risk of cancer.
